Key Points
-
Coordinated activity between somatostatin and gastrin-releasing peptide (GRP) regulates secretion of gastrin from G cells in a negative and positive manner, respectively, to facilitate the release of gastric acid from parietal cells.
-
In transgenic mouse models, hypergastrinaemia contributes to the development of atrophy in the proximal gastric mucosa through the induction of parietal cell apoptosis, leading to the development of gastric adenocarcinoma. This phenomenon has not been confirmed in human gastric cancer.
-
Infection with Helicobacter pylori is associated with increased gastrin levels in serum and components of the bacterium might activate the gastrin promoter directly and indirectly. Conversely, infection with H. pylori reduces somatostatin activity. Furthermore, GRP, somatostatin and gastrin seem to modulate the inflammatory response to the bacterium.
-
Gastrin and GRP have well-documented pro-carcinogenic roles, particularly in animal models, that affect proliferation, angiogenesis and apoptosis, whereas the potential pro-apoptotic signal of somatostatin is lost during carcinogenesis owing to weak expression of somatostatin receptor isoforms.
-
Clinical agonists and antagonists of the three hormones have shown modest activity in patients with gastrointestinal cancer, and rational combinations of these agents might prove to be more clinically beneficial.
Abstract
Gastrin is a pro-proliferative, anti-apoptotic hormone with a central role in acid secretion in the gastric mucosa and a long-standing association with malignant progression in transgenic mouse models. However, its exact role in human gastric malignancy requires further validation. Gastrin expression is tightly regulated by two closely associated hormones, somatostatin and gastrin-releasing peptide, and aspects of their interaction may be deregulated during progression to gastric adenocarcinoma. Furthermore, agonists and antagonists of the receptors for all three hormones have shown modest clinical efficacy against gastric adenocarcinoma, which might provide useful information on the future combined use of these agents.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Wiborg, O. et al. Structure of a human gastrin gene. Proc. Natl Acad. Sci. USA 81, 1067–1069 (1984).
Dickinson, C. J., Sawada, M., Guo, Y. J., Finniss, S. & Yamada, T. Specificity of prohormone convertase endoproteolysis of progastrin in AtT-20 cells. J. Clin. Invest. 96, 1425–1431 (1995).
Marino, L. R., Takeuchi, T., Dickinson, C. J. & Yamada, T. Expression and post-translational processing of gastrin in heterologous endocrine cells. J. Biol. Chem. 266, 6133–6136 (1991).
Lloyd, K. C. Gut hormones in gastric function. Baillieres Clin. Endocrinol. Metab. 8, 111–136 (1994). This review provides a detailed overview of the interactions between gastrin, somatostatin and GRP on the maintenance of stomach homeostasis.
Soll, A. H. & Grossman, M. I. The interaction of stimulants on the function of isolated canine parietal cells. Philos. Trans. R. Soc. Lond. B 296, 5–15 (1981).
Obrink, K. J. Histamine and gastric acid secretion. A review. Scand. J. Gastroenterol. Suppl. 180, 4–8 (1991).
Walsh, J. H. Physiology and pathophysiology of gastrin. Mt Sinai J. Med. 59, 117–124 (1992).
Chuang, C. N., Tanner, M., Chen, M. C., Davidson, S. & Soll, A. H. Gastrin induction of histamine release from primary cultures of canine oxyntic mucosal cells. Am. J. Physiol. 263, G460–G465 (1992).
Waldum, H. L. et al. The cellular localization of the cholecystokinin 2 (gastrin) receptor in the stomach. Pharmacol. Toxicol. 91, 359–362 (2002).
Lindstrom, E., Chen, D., Norlen, P., Andersson, K. & Hakanson, R. Control of gastric acid secretion:the gastrin–ECL cell-parietal cell axis. Comp. Biochem. Physiol. 128, 505–514 (2001).
Komazawa, Y. et al. Tolerance to famotidine and ranitidine treatment after 14 days of administration in healthy subjects without Helicobacter pylori infection. J. Gastroenterol. Hepatol. 18, 678–682 (2003).
Soll, A. H., Amirian, D. A., Thomas, L. P., Reedy, T. J. & Elashoff, J. D. Gastrin receptors on isolated canine parietal cells. J. Clin. Invest. 73, 1434–1447 (1984).
Helander, H. F., Wong, H., Poorkhalkali, N. & Walsh, J. H. Immunohistochemical localization of gastrin/CCK-B receptors in the dog and guinea-pig stomach. Acta Physiol. Scand. 159, 313–320 (1997).
Kopin, A. S. et al. Expression cloning and characterization of the canine parietal cell gastrin receptor. Proc. Natl Acad. Sci. USA 89, 3605–3609 (1992).
Cabero, J. L., Li, Z. Q. & Mardh, S. Gastrin potentiates histamine-stimulated aminopyrine accumulation in isolated rat parietal cells. Am. J. Physiol. 261, G621–G627 (1991).
Brenna, E. & Waldum, H. L. Studies of isolated parietal and enterochromaffin-like cells from the rat. Scand. J. Gastroenterol. 26, 1295–1306 (1991).
Kobayashi, T. et al. Abnormal functional and morphological regulation of the gastric mucosa in histamine H2 receptor-deficient mice. J. Clin. Invest. 105, 1741–1749 (2000).
Karnik, P. S. & Wolfe, M. M. Somatostatin stimulates gastrin mRNA turnover in dog antral mucosa. J. Biol. Chem. 265, 2550–2555 (1990).
Godley, J. M. & Brand, S. J. Regulation of the gastrin promoter by epidermal growth factor and neuropeptides. Proc. Natl Acad. Sci. USA 86, 3036–3040 (1989).
Park, J., Chiba, T. & Yamada, T. Mechanisms for direct inhibition of canine gastric parietal cells by somatostatin. J. Biol. Chem. 262, 14190–14196 (1987).
Prinz, C., Sachs, G., Walsh, J. H., Coy, D. H. & Wu, S. V. The somatostatin receptor subtype on rat enterochromaffinlike cells. Gastroenterology 107, 1067–1074 (1994).
Allen, J. P. et al. Identification of cells expressing somatostatin receptor 2 in the gastrointestinal tract of Sstr2 knockout/lacZ knockin mice. J. Comp. Neurol. 454, 329–340 (2002).
Reeve, J. R. Jr et al. Amino acid sequences of three bombesin-like peptides from canine intestine extracts. J. Biol. Chem. 258, 5582–5588 (1983).
Sugano, K., Park, J., Soll, A. H. & Yamada, T. Stimulation of gastrin release by bombesin and canine gastrin-releasing peptides. Studies with isolated canine G cells in primary culture. J. Clin. Invest. 79, 935–942 (1987).
Schubert, M. L., Hightower, J., Coy, D. H. & Makhlouf, G. M. Regulation of acid secretion by bombesin/GRP neurons of the gastric fundus. Am. J. Physiol. 260, G156–G160 (1991).
Hohenberger, P. & Gretschel, S. Gastric cancer. Lancet 362, 305–315 (2003).
La Vecchia, C., Negri, E., Franceschi, S. & Gentile, A. Family history and the risk of stomach and colorectal cancer. Cancer 70, 50–55 (1992).
Lauren, P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol. Microbiol. Scand. 64, 31–49 (1965).
Miyaji, H. et al. Helicobacter pylori infection occurs via close contact with infected individuals in early childhood. J. Gastroenterol. Hepatol. 15, 257–262 (2000).
Wang, L. D. et al. Changes in p53 and cyclin D1 protein levels and cell proliferation in different stages of human esophageal and gastric-cardia carcinogenesis. Int. J. Cancer 59, 514–519 (1994).
Takaishi, S. et al. Synergistic inhibitory effects of gastrin and histamine receptor antagonists on Helicobacter-induced gastric cancer. Gastroenterology 128, 1965–1983 (2005).
Delle Fave, G., Capurso, G., Milione, M. & Panzuto, F. Endocrine tumours of the stomach. Best Pract. Res. Clin. Gastroenterol. 19, 659–673 (2005).
Sekikawa, A. et al. REG Iα protein may function as a trophic and/or anti-apoptotic factor in the development of gastric cancer. Gastroenterology 128, 642–653 (2005).
Kazumori, H., Ishihara, S., Fukuda, R. & Kinoshita, Y. Localization of REG receptor in rat fundic mucosa. J. Lab. Clin. Med. 139, 101–108 (2002).
Fukui, H. et al. Regenerating gene protein may mediate gastric mucosal proliferation induced by hypergastrinemia in rats. Gastroenterology 115, 1483–1493 (1998).
Miyaoka, Y. et al. Transgenic overexpression of REG protein caused gastric cell proliferation and differentiation along parietal cell and chief cell lineages. Oncogene 23, 3572–3579 (2004).
Berman, D. M. et al. Widespread requirement for hedgehog ligand stimulation in growth of digestive tract tumours. Nature 425, 846–851 (2003). This study confirmed that the hedgehog pathway is essential for tumour growth through the induction of ligand expression and that this proliferation could be suppressed by the hedgehog pathway antagonist cyclopamine.
Osawa, H. et al. Sonic hedgehog stimulates the proliferation of rat gastric mucosal cells through ERK activation by elevating intracellular calcium concentration. Biochem. Biophys. Res. Commun. 344, 680–687 (2006).
Ma, X. et al. Frequent activation of the hedgehog pathway in advanced gastric adenocarcinomas. Carcinogenesis 26, 1698–1705 (2005).
Zavros, Y. et al. Gastrin-induced pepsinogen regulates sonic hedgehog processing and prevents gastric atrophy. Gastroenterology 130, A17 (2006).
Todisco, A. et al. Molecular mechanisms for the antiapoptotic action of gastrin. Am. J. Physiol. Gastrointest. Liver Physiol. 280, G298–G307 (2001). This paper overviews the signalling pathways through which gastrin can mediate anti-apoptotic activity in cancer.
Todisco, A. et al. Functional role of protein kinase B/AKT in gastric acid secretion. J. Biol. Chem. 276, 46436–46444 (2001).
Riobo, N. A., Lu, K., Ai, X., Haines, G. M. & Emerson, C. P. Jr. Phosphoinositide 3-kinase and AKT are essential for sonic hedgehog signaling. Proc. Natl Acad. Sci. USA 103, 4505–4510 (2006).
Stepan, V. et al. Regulation and function of the sonic hedgehog signal transduction pathway in isolated gastric parietal cells. J. Biol. Chem. 280, 15700–15708 (2005).
Dimmler, A. et al. Transcription of sonic hedgehog, a potential factor for gastric morphogenesis and gastric mucosa maintenance, is up-regulated in acidic conditions. Lab. Invest. 83, 1829–1837 (2003).
Wang, T. C. et al. Synergistic interaction between hypergastrinemia and Helicobacter infection in a mouse model of gastric cancer. Gastroenterology 118, 36–47 (2000). This is a milestone publication highlighting that Helicobacter infection and hypergastrinaemia interact during the development of gastric cancer.
Zavros, Y. et al. Chronic gastritis in the hypochlorhydric gastrin-deficient mouse progresses to adenocarcinoma. Oncogene 24, 2354–2366 (2005).
Helicobacter & Cancer Group. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut 49, 347–353 (2001).
Beales, I. et al. Effect of Helicobacter pylori products and recombinant cytokines on gastrin release from cultured canine G cells. Gastroenterology 113, 465–471 (1997). This study was the first to show that H. pylori products might contribute indirectly to hypergastri-naemia through the induction of cytokines that go on to potentiate gastrin release from the G cell.
Suzuki, T. et al. TNF-α and interleukin 1 activate gastrin gene expression via MAPK- and PKC-dependent mechanisms. Am. J. Physiol. Gastrointest. Liver Physiol. 281, G1405–G1412 (2001).
Beales, I. L. Gastrin and interleukin-1β stimulate growth factor secretion from cultured rabbit gastric parietal cells. Life Sci. 75, 2983–2995 (2004).
Dockray, G. J., Varro, A., Dimaline, R. & Wang, T. The gastrins: their production and biological activities. Annu. Rev. Physiol. 63, 119–139 (2001).
Kinoshita, Y. & Ishihara, S. Mechanism of gastric mucosal proliferation induced by gastrin. J. Gastroenterol. Hepatol. 15, D7–D11 (2000).
Zavros, Y. et al. Treatment of Helicobacter gastritis with IL-4 requires somatostatin. Proc. Natl Acad. Sci. USA 100, 12944–12949 (2003).
Kao, J. Y. et al. Somatostatin inhibits dendritic cell responsiveness to Helicobacter pylori. Regul. Pept. 134, 23–29 (2006).
Takhar, A., Eremin, O. & Watson, S. A. The role of gastrin in dendritic cell function. Br. J. Surg. 93 (Suppl. 3), A15 (2006).
Makarenkova, V. P. et al. Lung cancer-derived bombesin-like peptides down-regulate the generation and function of human dendritic cells. J. Neuroimmunol. 145, 55–67 (2003).
Rieder, G., Merchant, J. L. & Haas, R. Helicobacter pylori cag-type IV secretion system facilitates corpus colonization to induce precancerous conditions in Mongolian gerbils. Gastroenterology 128, 1229–12242 (2005). This is a milestone paper defining a potential mechanism through which H. pylori can directly activate gastrin gene transcription by the G cell and also might indicate a way through which non-endocrine malignant cells could gain an activated gastrin gene.
Walter, P., Gilmore, R. & Blobel, G. Protein translocation across the endoplasmic reticulum. Cell 38, 5–8 (1984).
Burgess, T. L. & Kelly, R. B. Constitutive and regulated secretion of proteins. Annu. Rev. Cell Biol. 3, 243–293 (1987).
Calam, J., Dockray, G. J., Walker, R., Tracy, H. J. & Owens, D. Molecular forms of gastrin in peptic ulcer: comparison of serum and tissue concentrations of G17 and G34 in gastric and duodenal ulcer subjects. Eur. J. Clin. Invest. 10, 241–247 (1980).
Dickinson, C. J., Daugherty, D., Guo, Y. J., Hughes, P. & Yamada, T. Molecular analysis of dibasic endoproteolytic cleavage signals. J. Biol. Chem. 267, 21795–21801 (1992).
Dickson, J., Grabowska, A., Atherton, J. & Watson, S. A. Role of gastrin in Helicobacter pylori induced HB-EGF gene up-regulation and ectodomain shedding. Gastroenterology 126, A59 (2004).
Dickson, J. H., Atherton, J. & Watson, S. A. Helicobacter pylori may up-regulate gastrin/CCK-2 receptor expression in exposed cells and human gastric mucosa. Gastroenterology 128, W1341 (2005).
Brzozowski, T. et al. Effect of probiotics and triple eradication therapy on the cyclooxygenase (COX)-2 expression, apoptosis, and functional gastric mucosal impairment in Helicobacter pylori-infected Mongolian gerbils. Helicobacter 11, 10–20 (2006).
Piotrowski, J., Skrodzka, D., Slomiany, A. & Slomiany, B. L. Reversal of gastric somatostatin receptor inhibition by Helicobacter pylori lipopolysaccharide with ebrotidine and sulglycotide. Gen. Pharmacol. 28, 705–708 (1997).
Guillermet, J. et al. Somatostatin receptor subtype 2 sensitizes human pancreatic cancer cells to death ligand-induced apoptosis. Proc. Natl Acad. Sci. USA 100, 155–160 (2003).
Beales, I. L. Effect of platelet-activating factor on gastrin release from cultured rabbit G-cells. Dig. Dis. Sci. 46, 301–306 (2001).
Li, H. C., Stoicov, C., Rogers, A. B. & Houghton, J. Stem cells and cancer: evidence for bone marrow stem cells in epithelial cancers. World J. Gastroenterol. 12, 363–371 (2006).
Kanda, N. et al. Involvement of cyclooxygenase-2 in gastric mucosal hypertrophy in gastrin transgenic mice. Am. J. Physiol. Gastrointest. Liver Physiol. 290, G519–G527 (2006).
Jensen, R. T. Consequences of long-term proton pump blockade: insights from studies of patients with gastri-nomas. Basic Clin. Pharmacol. Toxicol. 98, 4–19 (2006).
Laine, L., Ahnen, D., McClain, C., Solcia, E. & Walsh, J. H. Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibi-tors. Aliment. Pharmacol. Ther. 14, 651–668 (2000).
Mattsson, H. et al. Partial gastric corpectomy results in hypergastrinemia and development of gastric enterochromaffinlike-cell carcinoids in the rat. Gastroenterology 100, 311–319 (1991).
Havu, N. Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric secretion. Digestion 35, 42–55 (1986).
Havu, N., Mattsson, H., Ekman, L. & Carlsson, E. Enterochromaffin-like cell carcinoids in the rat gastric mucosa following long-term administration of ranitidine. Digestion 45, 189–195 (1990).
Hakanson, R. et al. Effects of antrectomy or portacaval shunting on the histamine-storing endocrine-like cells in oxyntic mucosa of rat stomach. A fluorescence histochemical, electron microscopic and chemical study. J. Physiol. 259, 785–800 (1976).
Simonsson, M. et al. Endocrine cells in the human oxyntic mucosa. A histochemical study. Scand. J. Gastroenterol. 23, 1089–1099 (1988).
Varro, A. et al. Processing of the gastrin precursor. Modulation of phosphorylated, sulfated, and amidated products. J. Biol. Chem. 265, 21476–21481 (1990).
Azuma, T., Taggart, R. T. & Walsh, J. H. Effects of bombesin on the release of glycine-extended progastrin (gastrin G) in rat antral tissue culture. Gastroenterology 93, 322–329 (1987).
Huebner, V. D. et al. Purification and structural characterization of progastrin-derived peptides from a human gastrinoma. J. Biol. Chem. 266, 12223–12227 (1991).
Azuma, T. et al. Carboxyl terminal glycine extended progastrin (gastrin-G) in gastric antral mucosa of patients with gastric or duodenal ulcer and in gastrinomas. J. Gastroenterol. Hepatol. 5, 525–529 (1990).
Chen, D. et al. Glycine-extended gastrin synergizes with gastrin-17 to stimulate acid secretion in gastrin deficient mice. Gastroenterology 116, 756–765 (1999).
Kuipers, E. J. et al. Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial. Gut 53, 12–20 (2004).
Eissele, R., Brunner, G., Simon, B., Solcia, E. & Arnold, R. Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia. Gastroenterology 112, 707–717 (1997).
Uemura, N. et al. Helicobacter pylori infection and the development of gastric cancer. N. Engl. J. Med. 345, 784–789 (2001).
Gillen, D. & McColl, K. E. Problems associated with the clinical use of proton pump inhibitors. Pharmacol. Toxicol. 89, 281–286 (2001).
Borch, K., Renvall, H., Liedberg, G. & Andersen, B. N. Relations between circulating gastrin and endocrine cell proliferation in the atrophic gastric fundic mucosa. Scand. J. Gastroenterol. 21, 357–363 (1986).
Solcia, E., Fiocca, R., Villani, L., Luinetti, O. & Capella, C. Hyperplastic, dysplastic, and neoplastic enterochromaffin-like-cell proliferations of the gastric mucosa. Classification and histogenesis. Am. J. Surg. Pathol. 19, S1–S7 (1995).
Delle Fave, G. et al. Hypergastrinemia and enterochromaffin-like cell hyperplasia. Yale J. Biol. Med. 71, 291–301 (1998).
Fich, A., Talley, N. J., Shorter, R. G. & Phillips, S. F. Zollinger–Ellison syndrome. Relation to Helicobacter pylori-associated chronic gastritis and gastric acid secretion. Dig. Dis. Sci. 36, 10–14 (1991).
Saeed, Z. A. et al. Helicobacter pylori and Zollinger–Ellison syndrome. Dig. Dis. Sci. 36, 15–18 (1991).
Weber, H. C., Venzon, D. J., Jensen, R. T. & Metz, D. C. Studies on the interrelation between Zollinger–Ellison syndrome, Helicobacter pylori, and proton pump inhibitor therapy. Gastroenterology 112, 84–91 (1997).
Hirschowitz, B. I. & Haber, M. M. Helicobacter pylori effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger–Ellison syndrome and non-Zollinger–Ellison syndrome acid hypersecretors treated long-term with lansoprazole. Aliment. Pharmacol. Ther. 15, 87–103 (2001).
Peghini, P. L. et al. Effect of chronic hypergastrinemia on human enterochromaffin-like cells: insights from patients with sporadic gastrinomas. Gastroenterology 123, 68–85 (2002).
El-Zimaity, H. M., Ota, H., Graham, D. Y., Akamatsu, T. & Katsuyama, T. Patterns of gastric atrophy in intestinal type gastric carcinoma. Cancer 94, 1428–1436 (2002).
Otsuka, T. et al. Coexistence of gastric- and intestinal-type endocrine cells in gastric and intestinal mixed intestinal metaplasia of the human stomach. Pathol. Int. 55, 170–179 (2005).
Correa, P. Chronic gastritis: a clinico-pathological classification. Am. J. Gastroenterol. 83, 504–509 (1988).
Henwood, M., Clarke, P. A., Smith, A. M. & Watson, S. A. Expression of gastrin in developing gastric adenocarcinoma. Br. J. Surg. 88, 564–568 (2001).
Watson, S. A., Morris, T. M., Varro, A., Michaeli, D. & Smith, A. M. A comparison of the therapeutic effectiveness of gastrin neutralisation in two human gastric cancer models: relation to endocrine and autocrine/paracrine gastrin mediated growth. Gut 45, 812–817 (1999).
Koh, T. J. & Chen, D. Gastrin as a growth factor in the gastrointestinal tract. Regul. Pept. 93, 37–44 (2000).
Hur, K. et al. Expression of gastrin and its receptor in human gastric cancer tissues. J. Cancer Res. Clin. Oncol. 132, 85–91 (2006). This is the most comprehensive study to date examining co-expression of gastrin and the CCK2 receptor on human gastric cancer tissues, including evaluation of their relationship to grade, sex and prognosis.
Merchant, J. L., Du, M. & Todisco, A. SP1 phosphorylation by ERK 2 stimulates DNA binding. Biochem. Biophys. Res. Commun. 254, 454–461 (1999).
Murayama, Y. et al. Localization of heparin-binding epidermal growth factor-like growth factor in human gastric mucosa. Gastroenterology 109, 1051–1059 (1995).
Madtes, D. K., Malden, L. T., Raines, E. W. & Ross, R. Induction of transcription and secretion of TGF-α by activated human monocytes. Chest 99, S79 (1991).
Mortensen, E. R., Marks, P. A., Shiotani, A. & Merchant, J. L. Epidermal growth factor and okadaic acid stimulate SP1 proteolysis. J. Biol. Chem. 272, 16540–16547 (1997).
Todisco, A., Seva, C., Takeuchi, Y., Dickinson, C. J. & Yamada, T. Somatostatin inhibits AP-1 function via multiple protein phosphatases. Am. J. Physiol. 269, G160–G166 (1995).
Bachwich, D., Merchant, J. & Brand, S. J. Identification of a cis-regulatory element mediating somatostatin inhibition of epidermal growth factor-stimulated gastrin gene transcription. Mol. Endocrinol. 6, 1175–1184 (1992).
Merchant, J. L. et al. ZBP-89, a Kruppel-like zinc finger protein, inhibits epidermal growth factor induction of the gastrin promoter. Mol. Cell. Biol. 16, 6644–6653 (1996).
Law, G. L. et al. Transcription factor ZBP-89 regulates the activity of the ornithine decarboxylase promoter. J. Biol. Chem. 273, 19955–19964 (1998).
Merchant, J. L., Tucker, T. P. & Zavros, Y. in Gastrin in the New Millennium (eds Merchant, J. L., Buchan, A. M. J. & Wang, T. C.) 55–70 (CURE Foundation, 2004).
Bai, L. & Merchant, J. L. ZBP-89 promotes growth arrest through stabilization of p53. Mol. Cell. Biol. 21, 4670–4683 (2001).
Koh, T. J. et al. Gastrin is a target of the β-catenin/TCF-4 growth-signaling pathway in a model of intestinal polyposis. J. Clin. Invest. 106, 533–539 (2000).
Zhang, Q. X., Dou, Y. L., Shi, X. Y. & Ding, Y. Expression of somatostatin mRNA in various differentiated types of gastric carcinoma. World J. Gastroenterol. 4, 48–51 (1998).
Patel, O., Shulkes, A. & Baldwin, G. S. Gastrin-releasing peptide and cancer. Biochim. Biophys. Acta 1766, 23–41 (2006).
Hu, C. et al. The effect of somatostatin and SSTR3 on proliferation and apoptosis of gastric cancer cells. Cancer Biol. Ther. 3, 726–730 (2004).
Preston, S. R., Woodhouse, L. F., Jones-Blackett, S., Wyatt, J. I. & Primrose, J. N. High affinity binding sites for gastrin releasing peptide on human gastric cancer and Menetrier's mucosa. Cancer Res. 53, 5090–5092 (1993).
Carroll, R. E., Carroll, R. & Benya, R. V. Characterization of gastrin-releasing peptide receptors aberrantly expressed by non-antral gastric adenocarcinomas. Peptides 20, 229–237 (1999). This paper shows that mutated isoforms of the GRP receptor are expressed by non-antral gastric adenocarcinoma.
Ramamoorthy, S., Stepan, V. & Todisco, A. Intracellular mechanisms mediating the anti-apoptotic action of gastrin. Biochem. Biophys. Res. Commun. 323, 44–48 (2004).
Ogasa, M. et al. Gastrin activates nuclear factor κB (NFκB) through a protein kinase C dependent pathway involving NFκB inducing kinase, inhibitor κB (IκB) kinase, and tumour necrosis factor receptor associated factor 6 (TRAF6) in MKN-28 cells transfected with gastrin receptor. Gut 52, 813–819 (2003).
Harris, J. C., Clarke, P. A., Awan, A., Jankowski, J. & Watson, S. A. An antiapoptotic role for gastrin and the gastrin/CCK-2 receptor in Barrett's esophagus. Cancer Res. 64, 1915–1919 (2004).
Harris, J. C., Clarke, P. & Watson, S. A. Gastrin mediated XIAP up-regulation and associated cisplatin resistance in the pre-malignant and malignant oesophagus. Gastroenterology 128 (Suppl. 3), A42 (2005).
Mao, J. D. et al. Correlation between expression of gastrin, somatostatin and cell apoptosis regulation gene BCL-2/BAX in large intestine carcinoma. World J. Gastroenterol. 11, 721–725 (2005).
Ferjoux, G. et al. Signal transduction of somatostatin receptors negatively controlling cell proliferation. J. Physiol. Paris 94, 205–210 (2000). This study defines how somatostatin receptor subtypes can mediate distinct signal-transduction pathways that inhibit proliferation, induce cell-cycle arrest and promote angiogenesis.
Sharma, K., Patel, Y. C. & Srikant, C. B. Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3. Mol. Endocrinol. 10, 1688–1696 (1996).
Theodoropoulou, M. et al. Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression. Cancer Res. 66, 1576–1582 (2006).
Qiao, J., Kang, J., Cree, J., Evers, B. M. & Chung, D. H. Gastrin-releasing peptide-induced down-regulation of tumor suppressor protein PTEN (phosphatase and tensin homolog deleted on chromosome ten) in neuro-blastomas. Ann. Surg. 241, 684–691; discussion 691–692 (2005).
Kinoshita, Y., Ishihara, S., Kadowaki, Y., Fukui, H. & Chiba, T. REG protein is a unique growth factor of gastric mucosal cells. J. Gastroenterol. 39, 507–513 (2004).
Fukui, H. et al. Effects of Helicobacter pylori infection on the link between regenerating gene expression and serum gastrin levels in Mongolian gerbils. Lab. Invest. 83, 1777–1786 (2003).
Pradeep, A. et al. Gastrin-mediated activation of cyclin D1 transcription involves β-catenin and CREB pathways in gastric cancer cells. Oncogene 23, 3689–3699 (2004).
Song, D. H. et al. Gastrin stabilises β-catenin protein in mouse colorectal cancer cells. Br. J. Cancer 92, 1581–1587 (2005).
Franco, A. T. et al. Activation of β-catenin by carcino-genic Helicobacter pylori. Proc. Natl Acad. Sci. USA 102, 10646–10651 (2005).
Wu, P. et al. Correlation between the expressions of gastrin, somatostatin and cyclin and cyclin-depend kinase in colorectal cancer. World J. Gastroenterol. 11, 7211–7217 (2005).
Xiao, D., Chinnappan, D., Pestell, R., Albanese, C. & Weber, H. C. Bombesin regulates cyclin D1 expression through the early growth response protein EGR-1 in prostate cancer cells. Cancer Res. 65, 9934–9942 (2005).
Tsutsui, S. et al. Induction of heparin binding epidermal growth factor-like growth factor and amphiregulin mRNAs by gastrin in the rat stomach. Biochem. Biophys. Res. Commun. 235, 520–523 (1997).
Miyazaki, Y. et al. Gastrin induces heparin-binding epidermal growth factor-like growth factor in rat gastric epithelial cells transfected with gastrin receptor. Gastroenterology 116, 78–89 (1999).
Tokunaga, A. et al. Clinical significance of epidermal growth factor (EGF), EGF receptor, and c-erbB-2 in human gastric cancer. Cancer 75, 1418–1425 (1995).
Thomas, S. M. et al. Gastrin-releasing peptide receptor mediates activation of the epidermal growth factor receptor in lung cancer cells. Neoplasia 7, 426–431 (2005).
Clarke, P. A., Dickson, J. H., Harris, J. C., Grabowska, A. & Watson, S. A. Gastrin enhances the angiogenic potential of endothelial cells via modulation of heparin binding epidermal-like growth factor. Cancer Res. 66, 3504–3512 (2006).
Guo, Y. S. et al. Gastrin stimulates cyclooxygenase-2 expression in intestinal epithelial cells through multiple signaling pathways. Evidence for involvement of ERK5 kinase and transactivation of the epidermal growth factor receptor. J. Biol. Chem. 277, 48755–48763 (2002).
Abdalla, S. I. et al. Gastrin-induced cyclooxygenase-2 expression in Barrett's carcinogenesis. Clin. Cancer Res. 10, 4784–4792 (2004).
Colucci, R. et al. Gastrin promotes human colon cancer cell growth via CCK-2 receptor-mediated cyclooxygenase-2 induction and prostaglandin E2 production. Br. J. Pharmacol. 144, 338–348 (2005).
Sun, W. H. et al. Expression of cyclooxygenase-2 and matrix metalloproteinase-9 in gastric carcinoma and its correlation with angiogenesis. Jpn J. Clin. Oncol. 35, 707–713 (2005).
Woltering, E. A. Development of targeted somatostatin-based antiangiogenic therapy: a review and future perspectives. Cancer Biother. Radiopharm. 18, 601–609 (2003).
Florio, T. et al. Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities. Endocrinology 144, 1574–1584 (2003).
Reubi, J. C. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr. Rev. 24, 389–427 (2003).
Levine, L. et al. Bombesin stimulates nuclear factor κB activation and expression of proangiogenic factors in prostate cancer cells. Cancer Res. 63, 3495–3502 (2003).
Ferrand, A. et al. Involvement of JAK2 upstream of the PI 3-kinase in cell-cell adhesion regulation by gastrin. Exp. Cell Res. 301, 128–138 (2004).
He, H., Pannequin, J., Tantiongco, J. P., Shulkes, A. & Baldwin, G. S. Glycine-extended gastrin stimulates cell proliferation and migration through a Rho- and ROCK-dependent pathway, not a Rac/Cdc42-dependent pathway. Am. J. Physiol. Gastrointest. Liver Physiol. 289, G478–G488 (2005).
Pagliocca, A. et al. Stimulation of the gastrin-cholecystokininB receptor promotes branching morphogenesis in gastric AGS cells. Am. J. Physiol. Gastrointest. Liver Physiol. 283, G292–G299 (2002).
Wroblewski, L. E., Pritchard, D. M., Carter, S. & Varro, A. Gastrin-stimulated gastric epithelial cell invasion: the role and mechanism of increased matrix metalloproteinase 9 expression. Biochem. J. 365, 873–879 (2002).
Chau, I. et al. Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials. Br. J. Cancer 94, 1107–11015 (2006).
Watson, S. A. et al. Gastrimmune raises antibodies that neutralize amidated and glycine-extended gastrin-17 and inhibit the growth of colon cancer. Cancer Res. 56, 880–885 (1996).
Gilliam, A. D. et al. A phase II study of G17DT in gastric carcinoma. Eur. J. Sur. Oncol. 30, 536–543 (2004).
Ajani, J. A. et al. An open-label, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5-fluorouracil in patients with untreated, advanced gastric or gastroesophageal cancer: the GC4 study. Cancer 106, 1908–1916 (2006).
Schwartsmann, G. et al. A phase I trial of the bombesin/gastrin-releasing peptide (BN/GRP) antagonist RC3095 in patients with advanced solid malignancies. Invest. New Drugs 24, 403–412 (2006).
Reubi, J. C., Waser, B., Schaer, J. C. & Laissue, J. A. Somatostatin receptor sst1–sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur. J. Nucl. Med. 28, 836–846 (2001). This remains the most comprehensive assessment of 'functional' somatostatin isoforms expressed by human gastric adenocarcinoma specimens.
Ferrand, A. & Wang, T. C. Gastrin and cancer: a review. Cancer Lett. 238, 15–29 (2005).
Asaka, M., Kudo, M., Kato, M., Sugiyama, T. & Takeda, H. Review article: long-term Helicobacter pylori infection--from gastritis to gastric cancer. Aliment. Pharmacol. Ther. 12, 9–15 (1998).
Dimaline, R. & Sandvik, A. K. Histidine decarboxylase gene expression in rat fundus is regulated by gastrin. FEBS Lett. 281, 20–22 (1991).
Fykse, V., Coy, D. H., Waldum, H. L. & Sandvik, A. K. Somatostatin-receptor 2 (sst2)-mediated effects of endogenous somatostatin on exocrine and endocrine secretion of the rat stomach. Br. J. Pharmacol. 144, 416–421 (2005).
Bakke, I., Qvigstad, G., Sandvik, A. K. & Waldrum, H. L. The CCK-2 receptor is located on the ECL cell, but not on the parietal cell. Scand. J. Gastroenterol. 11, 1128–1133 (2001).
Nakajima, T. et al. Gastrin stimulates the growth of gastric pit cell precursors by inducing its own receptors. Am. J. Physiol. Gastrointest. Liver Physiol. 282, G359–G366 (2002).
Schmidt, W. E. & Schmitz, F. Cellular localization of cholecystokinin receptors as the molecular basis of the periperal regulation of acid secretion. Pharmacol. Toxicol. 91, 351–358 (2002).
Schmitz, F. et al. CCK-B/gastrin receptors in human colo-rectal cancer. Eur. J. Clin. Invest. 31, 812–820 (2001).
Ito, M. et al. Functional characterization of two cholecystokinin-B/gastrin receptor isoforms: a preferential splice donor site in the human receptor gene. Cell Growth Differ. 5, 1127–1135 (1994).
Zhou, J. et al. Human gastric tissues coexpress two different splicing cholecystokinin-B/gastrin receptors. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi 21, 440–443 (2004).
Miyake, A. A truncated isoform of human CCK-B/gastrin receptor generated by alternative usage of a novel exon. Biochem. Biophys. Res. Commun. 208, 230–237 (1995).
Laghi, L. et al. Frameshift mutations of human gastrin receptor gene (hGARE) in gastrointestinal cancers with microsatellite instability. Lab. Invest. 82, 265–271 (2002).
Gugger, M., Waser, B., Kappeler, A., Schonbrunn, A. & Reubi, J. C. Cellular detection of sst2A receptors in human gastrointestinal tissue. Gut 53, 1431–1436 (2004).
van der Hoek, J., Hofland, L. J. & Lamberts, S. W. Novel subtype specific and universal somatostatin analogues: clinical potential and pitfalls. Curr. Pharm. Des. 11, 1573–1592 (2005).
Panteris, V. & Karamanolis, D. G. The puzzle of somatostatin: action, receptors, analogues and therapy. Hepatogastroenterology 52, 1771–1781 (2005).
Alderton, F., Fan, T. P., Schindler, M. & Humphrey, P. P. Rat somatostatin sst2(a) and sst2(b) receptor isoforms mediate opposite effects on cell proliferation. Br. J. Pharmacol. 125, 1630–1633 (1998).
Ohki-Hamazaki, H., Iwabuchi, M. & Maekawa, F. Development and function of bombesin-like peptides and their receptors. Int. J. Dev. Biol. 49, 293–300 (2005).
Acknowledgements
The authors would like to acknowledge J. McClelland from the Academic Unit of Cancer Studies for her input into the diagrams within this article and E. Royal for the personal communication regarding her ongoing studies.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Susan A. Watson is on the Scientific Advisory Board of Receptor Biologix, who have just purchased the rights to the drug G17DT.
Related links
Related links
DATABASES
Entrez Protein
FURTHER INFORMATION
Glossary
- Proton pump inhibitors
-
Agents that block acid secretion in the stomach and are used for the treatment of stomach ulcers.
- Enterochromaffin-like cell
-
A neuroendocrine cell, found in the gastric mucosa, that secretes histamine following hormonal stimulation.
- Antro-pyloric mucosa
-
The lower region of the stomach spanning the antrum and pylorus.
- Oxyntic mucosa
-
The region within the gastric mucosa that contains acid-secreting glands.
- Parietal cells
-
Cells of the gastric mucosa that produce gastric acid in response to histamine, gastrin or stimulation by the vagal nerve.
- Fundus
-
The dome-shaped upper part of the stomach.
- Secretagogue
-
A molecule that stimulates the secretion of gastric or pancreatic peptides.
- Lauren classification
-
A histological method for classifying gastric tumours into intestinal or diffuse type. The intestinal type is characterized by the formation of cohesive gland-like tubular structures, whereas the diffuse type involves infiltration and thickening of the stomach wall by individual cells.
- Signet ring
-
A poorly differentiated diffuse type of gastric cancer in which the nuclei of glandular cells are pushed aside by mucin vacuoles within the cell, giving them the appearance of a signet ring.
- Isthmus
-
The region of the gastric gland between the pit and neck that contains immature progenitor cells.
- Corpus
-
The main body of the stomach.
- Zymogenic cell
-
Also known as chief cells, these secrete pepsinogen and are characterized by spherical zymogen granules. They differentiate as they migrate downwards from the isthmus to the base of the gastric gland.
- Explosive exocytosis
-
The rapid release of the contents of cellular vesicles at the cell surface.
- Corpus atrophy
-
Loss of glandular structure within the corpus mucosa which is possibly accompanied by fibrosis, thinning of the lamina propria and replacement of gastric epithelium by intestinal metaplastic epithelium.
- Helicobacter felis
-
A strain of Helicobacter that was originally isolated from a cat and is also able to colonize mice and dogs.
- Pseudo-pyloric gland metaplasia
-
Gastric metaplasia in which gastric glands disappear and are replaced by tubules that closely resemble normal pyloric glands.
Rights and permissions
About this article
Cite this article
Watson, S., Grabowska, A., El-Zaatari, M. et al. Gastrin — active participant or bystander in gastric carcinogenesis?. Nat Rev Cancer 6, 936–946 (2006). https://doi.org/10.1038/nrc2014
Issue Date:
DOI: https://doi.org/10.1038/nrc2014
This article is cited by
-
Gastrin-17 induces gastric cancer cell epithelial-mesenchymal transition via the Wnt/β-catenin signaling pathway
Journal of Physiology and Biochemistry (2021)
-
Network pharmacology-based strategy to investigate pharmacological mechanisms of Zuojinwan for treatment of gastritis
BMC Complementary and Alternative Medicine (2018)
-
Whole genome MBD-seq and RRBS analyses reveal that hypermethylation of gastrointestinal hormone receptors is associated with gastric carcinogenesis
Experimental & Molecular Medicine (2018)
-
Acid and the basis for cellular plasticity and reprogramming in gastric repair and cancer
Nature Reviews Gastroenterology & Hepatology (2018)
-
Complexes of gastrin with In3+, Ru3+ or Ga3+ ions are not recognised by the cholecystokinin 2 receptor
JBIC Journal of Biological Inorganic Chemistry (2017)